AzTrials
AzTrials

Ultrafiltration FailureLUFFNCT05721703

An Observational Study of Long-term Peritoneal Dialysis Patients Who Eventually Develop Ultrafiltration Failure (LUFF)

An observational study of Ultrafiltration Failure, run by Chinese PLA General Hospital at 1 site in China.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

At present, there are few researches on peritoneal dialysis, especially on ultrafiltration failure of peritoneal dialysis. To explore the regularity and mechanism of peritoneal ultrafiltration failure,investigators followed up the comprehensive data of participants from the insertion to the removal of the peritoneal… Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Ultrafiltration Failure
How many people
150 participants
Where
1 siteChina
Study dates
21 May 2021to 31 Dec 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The patients who were diagnosed CKD5 age 18 to 70 need or keep peritoneal dialysis to treat or someone was ultrafiltration failure without AKI, pregnant or lactating women, active infection, infectious diseases and be asked to sign an "informed consent form".

Who may be able to join

  • Clinically diagnosed as chronic renal insufficiency (CKD 5)
  • Patients who met the first dialysis guidelines for peritoneal dialysis without catheter, or patients with peritoneal dialysis regularly, or ultrafiltration failure was diagnosed and patients on peritoneal dialysis were to be existed.
  • Written informed consent signed by the patient or the authorized client has been obtained.

Who cannot join

  • Acute renal failure.
  • Pregnant or lactating women.
  • Active infection duration.
  • One of infectious serum markers of HIV, syphilis, hepatitis B and hepatitis C is positive.
  • Any other conditions that the investigator considers impossible to join this trial.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, 100853

Other trials in China

About this study

Official title: Observe the Multi-indices of Long-term Peritoneal Dialysis Patients to Explore the Evolution of Peritoneal Ultrafiltration Failure

At present, there are few researches on peritoneal dialysis, especially on ultrafiltration failure of peritoneal dialysis. To explore the regularity and mechanism of peritoneal ultrafiltration failure,investigators followed up the comprehensive data of participants from the insertion to the removal of the peritoneal dialysis catheter, and collected the peritoneal tissue for morphological and single-cell analysis when the participants inserting or removing their catheters. If the catheter is still in use when this study stop collecting data, the peritoneal dialysis effluent will substitute for peritoneal tissue to the morphological and single-cell analysis. Clinical data and single-cell sequence data were processed using statistical analyses to identify factors affecting ultrafiltration failure.

Read the detailed description

Background: Chronic kidney disease (CKD) is one of the most common non-communicable diseases. The Global Burden of Disease (GBD), which examined multiple diseases in 188 countries from 1990 to 2013, found that the number of CKD patients increased from 318,665,000 to 47,1916,000, representing a 48% increase in prevalence (2.1% annually). Peritoneal dialysis is an important renal replacement therapy for participants with end-stage renal disease. The removal of water mainly depends on the high osmotic pressure of dialysate which is called ultrafiltration, and the loss of ultrafiltration function of peritoneum is called ultrafiltration failure. Data from the National Blood Purification Case Information System (CNRDS) show that the rate of conversion from ultrafiltration failure to hemodialysis is 5%-10%, and cardiovascular complications caused by fluid overload, such as malignant hypertension and heart failure, are the common causes of death. At the end of 2021, dialysis data in mainland China showed that there were nearly 880,000 patients undergoing dialysis treatment, of which 14% chose peritoneal dialysis, the average dialysis age of peritoneal dialysis patients was 50.3 months, the proportion of patients who had been on dialysis for more than 5 years was 33.9%, and the proportion of patients who had been on dialysis for more than 10 years was 7.5%. It can be seen that long-term peritoneal dialysis still has a high shedding rate, and ultrafiltration failure is the key problem of long-term peritoneal dialysis.

Methods: Investigators gathered participants from Department of Nephrology, PLA General Hospital, from May 2021 to May 2029. Inclusion Criteria: 1.Clinically diagnosed as chronic renal insufficiency (CKD 5); 2.Incident PD patients who were newly inserted PD catheter during the observation period of this study; 3.Prevalent PD patients who inserted PD cather before initiation of this study, should be admitted as pre-UFF, has taken long-term PD(>5 years) before removing cather during the observation period of this study; 4.Written informed consent signed by the patient or the authorized client has been obtained. Exclusion Criteria: 1.Acute renal failure; 2.Pregnant or lactating women; 3.Active infection duration; 4.One of infectious serum markers of HIV, syphilis, hepatitis B and hepatitis C is positive; 5.Any other conditions that the investigator considers impossible to join this trial. The observed indices were: (1)Demographic characteristics; (2)Peritoneal equilibration test (PET D/P), adequacy assessment(Ccr, Kt/V), evaluation of ultrafiltration (urine volume, intake,etc.); (3)Peritoneal dialysate routine examination, peritoneal dialysate inflammation examination and other markers and exosome examination; (4)Classification and counting of exfoliated cells from peritoneal dialysis effluent, and dialysate exfoliated cells primary culture for further cell biology analysis; (5)Peritoneal histopathology and immunohistochemical analysis and proteomics and single cell transcriptome analysis; (6)Clinical examinations: Routine blood test, Uroscopy, Blood biochemistry test, Coagulation function test, Immunoassay, Bone metabolism test, Thyroid function test, Evaluation of Ascites, etc. For an incident PD patient,after admission,the peritoneal catheter was inserted, and the data of the initial peritoneal equilibration test and clinical examinations were collected, and the peritoneal membrane was sampled for single-cell analysis. After that, the patient was followed up, and the data of the subsequent peritoneal equilibration test and clinical examinations were collected until the end point(technique failure) or the study end(8 years). The investigators collected the peritoneal tissue for single-cell sequencing when participants remove the catheters(for the technique failure patients). If the catheter is still in use when this study stop collecting data(8 years), the peritoneal dialysis effluent will substitute for peritoneal tissue to the morphological and single-cell analysis. For a prevalent patient who admitted as pre-UFF, investigators collected the final peritoneal equilibration test and clinical examination data then sample the peritoneal tissue for single-cell sequencing when removing the cather. SPSS and R were used for statistical analysis. Continuous variables were expressed as mean ± standard deviation, and discontinuous variables were expressed as percentage. The independent t-test or chi-square test was used for comparison between the two data. P<0.05 was statistically significant.

Keywords
peritoneal dialysis, Ultrafiltration Failure, long-term

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Technical survival rate

    Technical survival of peritoneal dialysis

    Measured: 8 year

Secondary outcomes (10)
  1. D/P

    Ratio of substance content in peritoneal dialysate to that in blood.

    Measured: 1,2,3,4,5,6,7,8 year

  2. OCG

    Glucose transport rates measured by a double mini peritoneal equilibration test.

    Measured: 1,2,3,4,5,6,7,8 year

  3. Ccr

    Creatinine clearance rate. Ccr=urinary creatinine concentration * urine volume per minute/blood creatinine concentration.

    Measured: 1,2,3,4,5,6,7,8 year

  4. Kt/V

    Ratio of urea clearance to volume during unit dialysis time.

    Measured: 1,2,3,4,5,6,7,8 year

  5. Cell counting

    Count the number of cells.

    Measured: 1,2,3,4,5,6,7,8 year

  6. Electrolyte

    Content of ions.

    Measured: 1,2,3,4,5,6,7,8 year

  7. Blood biochemical index

    Venous blood was obtained for biochemical examination.

    Measured: 1,2,3,4,5,6,7,8 year

  8. Urine protein

    Urine test for protein content.

    Measured: 1,2,3,4,5,6,7,8 year

  9. Histopathology

    With the consent of the patients, peritoneal tissue was taken to observe histological changes.

    Measured: 1,2,3,4,5,6,7,8 year

  10. Single-cell transcriptome sequencing

    With the consent of the patients, tissues were taken for analysis. Isolate cells in the tissues and measure gene expression profiles.

    Measured: 1,2,3,4,5,6,7,8 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Feb 2023
  2. Study start21 May 2021
  3. Primary completion31 Dec 2029 (estimated)
  4. Study completion31 Dec 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05721703
Sponsor's protocol ID
S2021-263-01
Acronym
LUFF
Status last verified
Feb 2023
First submitted
4 Oct 2022
Last updated
14 Feb 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Ultrafiltration Failure, run by Chinese PLA General Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 14 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Technical survival rate (time frame: 8 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in